Akiva Diamond

@VincentRK @mvmateos @ASH_hematology Really impressive! Honest question- what should be done with all the ongoing (or just opening) trials using Dpd/Dvd as a control arm? Would you still randomize?

This is the one of the most incredible outcome difference I have seen in myeloma: Results of the randomized Majestec-3 trial in myeloma. @mvmateos HR 0.17 !! Late breaker at #ASH25 @ASH_hematology meetings-api.hematology.org/api/abstract/v…

It was wonderful to speak with @AkivaDiamond at #ASCO25 today! He shared insights into the use of multi-virus-specific T-cells to enhance the activity of bispecific antibodies in lymphoma. Catch the full interview soon on VJHemOnc.com 📹 @ASCO #LYMsm #ImmunoOnc #HemOnc

@RShouval Really interesting and very cool study! I would love to see if this inflammation signature is applicable to other treatment settings (I.e. BsAb)

@RShouval It’s possible that inflamed may be prognostic but not predictive. Perhaps it’s a epiphenomenon- more aggressive tumor biology increasing inflammation. prognostic value of becoming non-inflamed at infusion may reflect chemo sensitivity. I doubt window Toci/Anakinra would help

🚨 Just out @NatureMedicine! Introducing InflaMix—a point-of-care tool that identifies an #inflammatory 🔥 signature predictive of #CART failure in #lymphoma Led by Sandeep Raj (@SSRaj017) 👏@MSKCancerCenter nature.com/articles/s4159… 🧵Let’s break it down

@graham74GC @vit_prochazka The data hasn’t really changed and the press release implies that the main change was they negotiated a better price with Takeda. Am I being too cynical to think they were willing to give a better price since most US based centers shifted to Nivo?

@vit_prochazka We are strictly bound by what is reimbursed and nivo-AVD and BrECADD are a long way off. So yes we will be using it.

Great news - NICE have approved AVD-BV for 1L treatment of advanced stage Hodgkin Lymphoma. Great to have an additional option for these patients. #lymsm nice.org.uk/news/articles/…

@majorajay Did they discuss why OS is > PFS? 2nd line r-mini-CHOP?

Epco monotherapy in age >75 DLBCL #ASH24: - 45 pts, 38% age >85, all anthracycline ineligible - ORR 69%, CR 62% - 6-mo DOR 82%, PFS 73%, OS 81% - 5 fatal TEAEs (COVID, CMV, TLS), 8 pts d/c'd d/t TEAEs Seems fairly toxic; some debulking needed prior? #lymsm #gerionc

@Eddie_Cliff @BroeckelmannPJ The PFS overall is disappointing given median lines of prior therapy was 1, but happy to see the difference between their patients and those treated on augment. The R2 PFS looked similar to the R monotherapy arm of augment.

More details on toxicity and AEs - so much more reliable to interpret in a double blind study!! cc @BroeckelmannPJ #ASH24

LBA1 InMIND, Laurie Sehn RCT of CD19 mAb tafasitamab + R2 vs placebo + R2, double blind PFS benefit - median 22.4mo vs 13.9mo AUGMENT pt characteristics included to explain poor PFS seen in control arm Congrats to investigators for double blinding #ASH24 #lymsm

@graham74GC My takeaway was more the lack of benefit over BR. “For the subgroup with selection BR, the HR = 1.00 (0.70, 1.44), 5 year OS probability 57.2% vs 58.1%, for IR and BR, respectively.”

Lewis et al - ENRICH trial: Ibr+R vs R-chemo 1L MCL - >60y, R-CHOP or R-benda as control - Signif PFS adv for IR esp when R-CHOP is control - Cardiac AEs 22% in IR arm - Blastoid did less well with IR First trial of chemo-free vs chemo in 1L MCL: it's positive! #ASH24

Baylor College of Medicine is seeking a full-time classical hematologist to join our clinical and research programs. We are located in the heart of Houston (not Waco): jobcenter.hematology.org/job/14341

@RahulBanerjeeMD @GKaurMD @BoWangMD1 @ldandersonjr @VincentRK Really interested to see what percent actual use twice weekly in routine clinical care

@AkivaDiamond @GKaurMD @BoWangMD1 @ldandersonjr @VincentRK Us as well - I don’t think there will be one practice type / setting / country that disproportionately uses twice-weekly Velcade in #MMsm, but we will find out… 🙏 again!

🚨 Help us figure out how #MMsm myeloma world prescribes bortezomib (Velcade): once-weekly vs twice-weekly, subQ vs IV, etc. Quick 2-3 minute survey 👇 redcap.link/velcade We'd love responses from all oncologists across all countries & practice types. Thanks for your time!

@RahulBanerjeeMD @GKaurMD @BoWangMD1 @ldandersonjr @VincentRK Looking forward to seeing the results.

Despite bortezomib being >20 yrs old, we (including @GKaurMD @BoWangMD1 @ldandersonjr @VincentRK) suspect there will be significant heterogeneity in #MMsm practice patterns & rationales. Help prove us right or wrong - thanks in advance! 🙏 Survey link: redcap.link/velcade

Data is finally out! median follow-up of 12.1 months, PFS was superior in the N-AVD arm [HR 0.48, 99% CI 0.27-0.87) 1y PFS: N-AVD: 94% BV-AVD: 86%

It’s interesting to note that ibrutinib approval seems to be associated with decreased BR use but chlorambucil rates remained low and steady.

Our data show that in the period when chlorambucil was used as a control arm in ibrutinib trials, CLL patients of comparable age were more commonly treated with more aggressive therapies

Excited to share our paper published in @LeukemiaJnl “Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials” nature.com/articles/s4137… We were interested to look at treatment patterns during the era of the early ibrutinib trials 🧵 1/n